THE EFFICIENCY, SAFETY, AND TOLERANCE OF ROSUVASTATIN THERAPY IN VERY HIGH CARDIOVASCULAR RISK PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: PRELIMINARY RESULTS OF THE 40x40 STUDY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The main objective of the pilot 40 x 40 study was to evaluate the hypolipidemic efficacy, safety, and tolerance of the generic rosuvastatin Mertenil in a high daily dose of 40 mg/day in very high cardiovascular risk patients who failed to achieve low-density lipoprotein cholesterol goals during current statin therapy in daily clinical practice. The data of a follow-up during the first 12-week therapy are given.

Full Text

Restricted Access

About the authors

M. Zubareva

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
Candidate of Medical Sciences

T. Rozhkova

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
Candidate of Medical Sciences

N. Gornyakova

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
Candidate of Medical Sciences

E. Solovyeva

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
Candidate of Medical Sciences

A. Susekov

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
MD

V. Kukharchuk

Russian Cardiology Research-and-Production Complex, Ministry of Health and Social Development of Russia

Email: asus99@mail.ru
MD, Correspondent Member of the Russian Academy of Medical Sciences Laboratory of Clinical Lipidology, Department of Atherosclerosis Problems

References

  1. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. - 2011; 32 (14): 1769-818.
  2. Cholesterol Treatment Trialist’s CTT Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins // Lancet. - 2005; 366: 1267-78.
  3. CTT Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials // Lancet. - 2010; 376: 1670-81.
  4. CTT Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials // Lancet. - 2012; 380 (9841): 581-90.
  5. Law M., Wald N., Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis // BMJ. - 2003; 326 (7404): 1423.
  6. Jones P., Davidson M., Stein E. et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) // Am. J. Cardiol. - 2003; 92 (2): 152-60.
  7. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. 5-й пересм. - М., 2012.
  8. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П. и др. Сохраняющиеся нарушения липидного спектра у пациентов с дислипидемиями, получающих статины в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS) // Кардиоваск. тер. и профилакт. - 2012; 4: 1-10.
  9. Константинов В.О. Новое в профилактике атеросклероза и его осложнений // Справ. поликлинич. врача. - 2012; 2: 7-12.
  10. Stalenhoef A., Ballantyne C., Sarti C. et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study // Eur. Heart J. - 2005; 26: 2664-72.
  11. Strandberg T., Feely J., Sigurdsson E. DISCOVERY study group. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study // Clin. Ther. - 2004; 26 (11): 1821-33.
  12. Sorof J., Berne Ch., Siewert-Delle A. et al. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients // Diab. Res. Clin. Practice. - 2006; 72: 81-7.
  13. Schuster H., Barter P., Stender S. et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study // Am. Heart J. - 2004; 147: 705-12.
  14. Ballantyne C., Raichlen J., Cain V. Statin Therapy Alters the RelationshipBetween Apolipoprotein B and Low-Density Lipoprotein Cholesterol. and Non-High-Density Lipoprotein Cholesterol. Targets in High-Risk PatientsThe MERCURY II (Measuring EffectiveReductions in Cholesterol Using Rosuvastatin therapY II) // Trial. J. Am. Coll. Cardiol. - 2008; 52: 626-32.
  15. Betteridge D., Gibson J., Sager Ph. Comparison of Effectiveness of Rosuvastatin Versus Atorvastatin on the Achievement of Combined C-Reactive Protein (<2 mg/L) and Low-Density Lipoprotein Cholesterol (<70 mg/dl) Targets in Patients With Type 2 Diabetes Mellitus (from the ANDROMEDA Study) // Am. J. Cardiol. - 2007; 100: 1245-8.
  16. Pitt B., Loscalzo J., Monyak J. et al. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study) // Am. J. Cardiol. 2012; 109: 1239-46.
  17. Задионченко В.С., Шахрай Н.Б., Шехян Г.Г. и др. Особенности фармакологических и клинических свойств розувастатина // Рус. мед. журн. - 2011; 12: 772-8.
  18. Задионченко В.С., Шехян Г.Г., Шахрай Н.Б. и др. Влияние розувастатина на липидный обмен, микроциркуляцию и показатели центральной гемодинамики у больных с острым коронарным синдромом // Consilium Medicum. -2011; 5: 85-9.
  19. Гиляревский С.Р., Орлов В.А., Кузьмина И.М. и др. Гиполипидемические эффекты интенсивных режимов применения статинов при лечении больных с острым коронарным синдромом: подходы к выбору препарата и его дозы // Кардиол. и сердечно-сосуд. хир. - 2012; 5 (4): 36-41.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies